Skip to main
GOVX
GOVX logo

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is positioned favorably within the expanding biodefense industry, which has gained momentum following heightened global awareness of biological threats. The company's commitment to vaccine accessibility and sustainability, particularly for Clade 1-endemic regions, aligns with significant government funding aimed at accelerating vaccine development and deployment. Additionally, Geovax's diverse vaccine pipeline, which includes innovative programs targeting emerging infectious diseases and solid tumor cancers, underscores the potential for strong future revenue streams as these initiatives progress.

Bears say

Geovax Labs faces a negative outlook primarily due to the high cost of its preferred COVID-19 vaccine, which at $270 per dose, poses significant barriers to widespread vaccination and exacerbates global access inequalities. Delays in vaccine distribution and limited production capacity, particularly in Africa, have resulted in substantial vaccine stockpiles that remain largely unused, highlighting logistical and political challenges that further impede equitable access. Additionally, reliance on a single supplier for vaccine distribution increases the risk of supply chain disruptions, underscoring the inadequacy of current global efforts to meet vaccination needs effectively.

Geovax Labs (GOVX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.